Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.65 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.52 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12004704 | 0.98 | LMNA (0.69) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Hydrochloric Acid SCHEMBL12005237 | 0.98 | LMNA (0.69) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL1031729 | 0.97 | LMNA (0.71) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL18633373 | 0.88 | LMNA (0.68) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Trifluoroacetic Acid SCHEMBL29174391 | 0.85 | LMNA (0.60) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL28927348 | 0.83 | LMNA (0.76) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL40922 | 0.83 | LMNA (0.97) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Hydrochloric Acid SCHEMBL28018868 | 0.83 | LMNA (0.69) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL5595814 | 0.83 | LMNA (0.97) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL18952886 | 0.83 | LMNA (0.97) | LMNAMAPK1ALDH1A1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO- CLINIC" (NL) | 2015-06-04 | — | — | US | disclosed |
| US-8980932-B2 | Cancer targeting using carbonic anhydrase isoform IX inhibitors | Stichting Maastricht Radiation Oncology “Maastro-Clinic” (NL) | 2015-03-17 | — | — | US | disclosed |
| EP-2655336-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO CLINIC" (NL) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | Supuran, Claudiu (IT) | 2013-10-17 | — | — | US | disclosed |
| WO-2012087115-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2012-06-28 | — | — | WO | disclosed |
| CN-101203249-A | Poly (peptide) as chelating agent: method of manufacture and use | UNIV TEXAS (US) | 2008-06-18 | — | — | CN | disclosed |
| US-20060246005-A1 | Poly(peptide) as a chelator: methods of manufacture and uses | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | CA2 5/4885GLA 1625/4885GAA 118/4885 |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | CA2 5/4885GLA 2081/4885GAA 102/4885 |
| US-20060246005-A1 | Poly(peptide) as a chelator: methods of manufacture and uses | VIP, NGLY1, DNPEP | CA2 690/4885GLA 1468/4885GAA 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.